Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.032
Neutral
RSI(14)
46.534
Neutral
STOCH(KDJ)(9,3,3)
61.583
Neutral
ATR(14)
0.208
High Vlolatility
CCI(14)
6.533
Neutral
Williams %R
50.336
Neutral
TRIX(12,20)
0.101
Sell
StochRSI(14)
29.097
Sell
Search
Organogenesis Holdings Inc
ORGOAdd to Watchlist
2.410USD
-0.180-6.95%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
310.11MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Organogenesis Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Organogenesis Holdings Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 32 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Organogenesis Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Organogenesis Holdings Inc Highlights
StrengthsRisks
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.25% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 564.17M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is -21.81, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.97M shares, decreasing 7.21% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 139.54K shares of this stock.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
8.000
Target Price
+208.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Organogenesis Holdings Inc is 8.77, ranking 24 out of 382 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 37.23M, representing a year-over-year decrease of 57.06%, while its net profit experienced a year-over-year decrease of 160.10%.
Score
Financials
7.67
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.37
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.81
Organogenesis Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Organogenesis Holdings Inc is 6.30, ranking 289 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.81, which is -646.36% below the recent high of 119.16 and -3899.04% above the recent low of -872.19.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 32/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Organogenesis Holdings Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 9.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
8.000
Target Price
+208.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Organogenesis Holdings Inc
ORGO
1
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Organogenesis Holdings Inc is 7.37, ranking 72 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.78 and the support level at 2.04, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.488
Sell
MA10
2.505
Sell
MA20
2.454
Sell
MA50
2.459
Sell
MA100
3.272
Sell
MA200
4.011
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Organogenesis Holdings Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 55.15%, representing a quarter-over-quarter increase of 0.09%. The largest institutional shareholder is James Simons, holding a total of 1.07M shares, representing 0.83% of shares outstanding, with 0.95% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Organogenesis Holdings Inc is 3.22, ranking 155 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.30
VaR
+6.44%
240-Day Maximum Drawdown
+65.75%
240-Day Volatility
+80.27%
Return
Best Daily Return
60 days
+12.03%
120 days
+12.03%
5 years
+102.28%
Worst Daily Return
60 days
-13.24%
120 days
-13.24%
5 years
-42.70%
Sharpe Ratio
60 days
-2.64
120 days
-2.26
5 years
-0.00
Risk Assessment
Maximum Drawdown
240 days
+65.75%
3 years
+65.75%
5 years
+88.92%
Return-to-Drawdown Ratio
240 days
-0.14
3 years
-0.14
5 years
-0.19
Skewness
240 days
+3.19
3 years
+5.97
5 years
+5.19
Volatility
Realised Volatility
240 days
+80.27%
5 years
+79.37%
Standardised True Range
240 days
+10.14%
5 years
+12.14%
Downside Risk-Adjusted Return
120 days
-326.89%
240 days
-326.89%
Maximum Daily Upside Volatility
60 days
+58.21%
Maximum Daily Downside Volatility
60 days
+56.94%
Liquidity
Average Turnover Rate
60 days
+1.17%
120 days
+1.02%
5 years
--
Turnover Deviation
20 days
+28.43%
60 days
+26.49%
120 days
+10.21%
Peer Comparison
Biotechnology & Medical Research
Organogenesis Holdings Inc
ORGO
7.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
